Quantbot Technologies LP Reata Pharmaceuticals Inc Transaction History

Quantbot Technologies LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$30.85 - $93.17 $115,934 - $350,132	-3,758 Reduced 38.7%	5,952 $541,000
Q4 2022 Feb 13, 2023	SELL	$22.15 - $42.11 $93,450 - $177,662	-4,219 Reduced 30.29%	9,710 $368,000
Q3 2022 Nov 07, 2022	BUY	$19.41 - $36.49 $270,361 - $508,269	13,929 New	13,929 $350,000
Q3 2021 Nov 09, 2021	SELL	$100.0 - $143.02 $119,300 - $170,622	-1,193 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$78.27 - $151.29 $87,818 - $169,747	1,122 Added 1580.28%	1,193 $168,000
Q1 2021 May 14, 2021	SELL	$94.25 - $132.81 $24,787 - $34,929	-263 Reduced 78.74%	71 $7,000
Q4 2020 Feb 12, 2021	SELL	$102.03 - $184.62 $83,970 - $151,942	-823 Reduced 71.13%	334 $41,000
Q3 2020 Nov 16, 2020	BUY	$93.53 - $163.34 $108,214 - $188,984	1,157 New	1,157 $112,000
Q2 2020 Aug 13, 2020	SELL	$126.3 - $176.56 $17,050 - $23,835	-135 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$124.16 - $247.74 $16,761 - $33,444	135 New	135 $19,000
Q3 2018 Nov 13, 2018	SELL	$35.64 - $92.06 $119,465 - $308,585	-3,352 Closed	0 $0
Q2 2018 Aug 13, 2018	BUY	$19.94 - $40.96 $66,838 - $137,297	3,352 New	3,352 $117,000

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Quantbot Technologies LP, based on Form 13F filings with the SEC.

Stay updated on Quantbot Technologies LP with notifications on news.